BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bausch & Lomb (BOL), Santen Pharmaceutical Strike Licensing Agreement for IOL Development


3/3/2009 8:27:30 AM

ALISO VIEJO, Calif., March 3 /PRNewswire/ -- Bausch & Lomb, the global eye health company, has entered into a licensing agreement with Santen Pharmaceutical Co., Ltd., for the development of certain intraocular lens (IOL) materials.

Under the terms of the agreement, Bausch & Lomb has obtained the rights to Santen's hydrophobic acrylic polymers, from which it may commercialize new IOLs for sale worldwide. Santen reserves the right for the use of these materials in the Japanese market. Financial terms will not be disclosed.

"Bausch & Lomb is enthusiastic about the potential that these polymers hold for developing next-generation IOLs, to benefit patients and surgeons alike," said John Sheets, Jr., Ph.D., corporate vice president and chief technology officer, Bausch & Lomb. "We are committed to aggressively creating innovative, in-demand products through both industry partnerships and our considerable internal capabilities. Combining these materials with our current product and technology portfolio will provide Bausch & Lomb with an unsurpassed breadth of product offerings."

"Developing these novel materials extends our access to the global IOL marketplace, complementing our existing Crystalens(R), Akreos(TM) and SofPort(R) IOL products," noted Tom Frinzi, vice president, Global Commercial Operations, Surgical, Bausch & Lomb.

Bausch & Lomb is one of the world's leading developers and manufacturers of IOLs, which are used to replace the eye's natural crystalline lens during cataract surgery. Its Crystalens product is the only FDA-approved accommodating IOL, flexing like the eye's natural lens to allow patients to see better at all distances.

About Bausch & Lomb

Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for people around the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Bausch & Lomb is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y. Its products are available in more than 100 countries. More information is available at www.bausch.com.

Akreos, SofPort, and Crystalens are trademarks of Bausch & Lomb Incorporated.

CONTACT: Mike McDougall, APR, Vice President, Corporate Communications and
Public Affairs, Bausch & Lomb, +1-585-338-5469, mmcdougall@bausch.com

Web site: http://www.bausch.com/


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->